Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 35926098)

  • 1. Panitumumab-DOTA-
    Facca VJ; Cai Z; Gopal NEK; Reilly RM
    Mol Pharm; 2022 Oct; 19(10):3652-3663. PubMed ID: 35926098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant Auger Electron-Emitting Radioimmunotherapy with [
    Facca VJ; Cai Z; Ku A; Georgiou CJ; Reilly RM
    Mol Pharm; 2023 Dec; 20(12):6407-6419. PubMed ID: 37983089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [
    Boyle AJ; Cao PJ; Cai Z; Chan C; Hedley DW; Reilly RM
    Nucl Med Biol; 2020; 84-85():46-54. PubMed ID: 32062317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
    Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
    Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting,
    Aghevlian S; Cai Z; Hedley D; Winnik MA; Reilly RM
    EJNMMI Radiopharm Chem; 2020 Nov; 5(1):22. PubMed ID: 33169241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
    Chan C; Fonge H; Lam K; Reilly RM
    Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with
    Ku A; Chan C; Aghevlian S; Cai Z; Cescon D; Bratman SV; Ailles L; Hedley DW; Reilly RM
    Mol Pharm; 2019 Aug; 16(8):3559-3568. PubMed ID: 31242384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelating Polymers Complexed to
    Aghevlian S; Cai Z; Lu Y; Hedley DW; Winnik MA; Reilly RM
    Mol Pharm; 2019 Feb; 16(2):768-778. PubMed ID: 30589553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation Nanomedicine for EGFR-Positive Breast Cancer: Panitumumab-Modified Gold Nanoparticles Complexed to the β-Particle-Emitter, (177)Lu.
    Yook S; Cai Z; Lu Y; Winnik MA; Pignol JP; Reilly RM
    Mol Pharm; 2015 Nov; 12(11):3963-72. PubMed ID: 26402157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with
    Yook S; Cai Z; Jeong JJ; Lu Y; Winnik MA; Pignol JP; Reilly RM
    Mol Pharm; 2020 Apr; 17(4):1226-1236. PubMed ID: 32022567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose predictions for [
    Ku A; Kondo M; Cai Z; Meens J; Li MR; Ailles L; Reilly RM
    EJNMMI Radiopharm Chem; 2021 Aug; 6(1):25. PubMed ID: 34383182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.
    Fasih A; Fonge H; Cai Z; Leyton JV; Tikhomirov I; Done SJ; Reilly RM
    Breast Cancer Res Treat; 2012 Aug; 135(1):189-200. PubMed ID: 22736376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice.
    Panosa C; Fonge H; Ferrer-Batallé M; Menéndez JA; Massaguer A; De Llorens R; Reilly RM
    Nucl Med Biol; 2015 Dec; 42(12):931-8. PubMed ID: 26385534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [
    Kondo M; Cai Z; Chan C; Forkan N; Reilly RM
    EJNMMI Radiopharm Chem; 2023 Sep; 8(1):24. PubMed ID: 37750937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [
    Facca VJ; Al-Saden N; Ku A; Reilly RM
    Mol Imaging Biol; 2021 Aug; 23(4):495-504. PubMed ID: 33479914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab.
    Liu Z; Liu Y; Jia B; Zhao H; Jin X; Li F; Chen X; Wang F
    Mol Cancer Ther; 2010 Aug; 9(8):2297-308. PubMed ID: 20682654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical studies of a PARP targeted, Meitner-Auger emitting, theranostic radiopharmaceutical for metastatic ovarian cancer.
    Hoffman SLV; Mixdorf JC; Kwon O; Johnson TR; Makvandi M; Lee H; Aluicio-Sarduy E; Barnhart TE; Jeffery JJ; Patankar MS; Engle JW; Bednarz BP; Ellison PA
    Nucl Med Biol; 2023; 122-123():108368. PubMed ID: 37490805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF.
    Cai Z; Chen Z; Bailey KE; Scollard DA; Reilly RM; Vallis KA
    J Nucl Med; 2008 Aug; 49(8):1353-61. PubMed ID: 18632822
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Cai Z; Chattopadhyay N; Yang K; Kwon YL; Yook S; Pignol JP; Reilly RM
    Nucl Med Biol; 2016 Dec; 43(12):818-826. PubMed ID: 27788375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.